ECSP055537A - Monoclorhidrato de 2,5-diona-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirrol cristalino - Google Patents

Monoclorhidrato de 2,5-diona-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirrol cristalino

Info

Publication number
ECSP055537A
ECSP055537A EC2005005537A ECSP055537A ECSP055537A EC SP055537 A ECSP055537 A EC SP055537A EC 2005005537 A EC2005005537 A EC 2005005537A EC SP055537 A ECSP055537 A EC SP055537A EC SP055537 A ECSP055537 A EC SP055537A
Authority
EC
Ecuador
Prior art keywords
indol
piperidin
methyl
monoclorhydrate
ilmetil
Prior art date
Application number
EC2005005537A
Other languages
English (en)
Inventor
Julie Kay Bush
Margaret Mary Faul
Susan Marie Reutzel-Edens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42799191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055537(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP055537A publication Critical patent/ECSP055537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a la sal monoclorhidrato de 2,5-diona-3-(1-metil-1H-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1H-indol-3-il]-1H-pirrol cristalino, a una formulación farmacéutica que contenga dicha sal y a procedimientos de tratamiento del cáncer y de inhibición del crecimiento tumoral utilizando dicha sal.
EC2005005537A 2002-07-12 2005-01-12 Monoclorhidrato de 2,5-diona-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirrol cristalino ECSP055537A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39597602P 2002-07-12 2002-07-12

Publications (1)

Publication Number Publication Date
ECSP055537A true ECSP055537A (es) 2005-03-10

Family

ID=42799191

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005537A ECSP055537A (es) 2002-07-12 2005-01-12 Monoclorhidrato de 2,5-diona-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirrol cristalino

Country Status (21)

Country Link
US (2) US8114901B2 (es)
EP (1) EP1523313B1 (es)
JP (2) JP4771356B2 (es)
KR (1) KR100687165B1 (es)
CN (1) CN100430058C (es)
AU (1) AU2003280958B9 (es)
CA (1) CA2393720C (es)
DE (1) DE60317675T2 (es)
EA (1) EA007463B1 (es)
EC (1) ECSP055537A (es)
ES (1) ES2295605T3 (es)
HR (1) HRP20050035B1 (es)
IL (1) IL165747A (es)
NO (1) NO330254B1 (es)
NZ (1) NZ537137A (es)
PE (1) PE20040652A1 (es)
PL (1) PL373046A1 (es)
TW (1) TWI315667B (es)
UA (1) UA78801C2 (es)
WO (1) WO2004006928A1 (es)
ZA (1) ZA200500065B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1845974A1 (en) 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
US20110009847A1 (en) 2009-03-02 2011-01-13 Seventh Sense Biosystems, Inc. Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin
WO2011094573A1 (en) 2010-01-28 2011-08-04 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
ES2561824T3 (es) 2010-07-16 2016-03-01 Seventh Sense Biosystems, Inc. Ambiente a baja presión para dispositivos de transferencia de fluidos
EP2630121A1 (en) * 2010-09-30 2013-08-28 Wisconsin Alumni Research Foundation (20r,25s)-2-methylene-19,26-dinor-1alpha, 25-dihydroxyvitamin d3 in crystalline form
ES2565805T3 (es) 2010-11-09 2016-04-07 Seventh Sense Biosystems, Inc. Sistemas e interfaces para el muestreo de sangre
KR102237667B1 (ko) 2011-04-29 2021-04-12 세븐쓰 센스 바이오시스템즈, 인크. 유체들의 전달 및/또는 수용
CA3028114A1 (en) 2016-06-17 2017-12-21 Universidad De Los Andes Gelatin polymer derived from natural sources of cold-adapted marine species and uses thereof
CN109789141B (zh) * 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3625738A1 (de) * 1986-07-30 1988-02-11 Goedecke Ag 2-acyloxypropylamin-derivate, verfahren zu deren herstellung und deren verwendung
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
DE3803620A1 (de) 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5489608A (en) * 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE4243321A1 (de) 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
SE501711C2 (sv) * 1993-09-08 1995-05-02 Jimek Int Ab Sprayrör för en duktvättanordning vid en tryckpress
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride
AU1189201A (en) 1999-10-22 2001-05-08 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
WO2002002116A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
JP2005531609A (ja) * 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体

Also Published As

Publication number Publication date
PE20040652A1 (es) 2004-10-05
NZ537137A (en) 2007-11-30
CA2393720C (en) 2010-09-14
TWI315667B (en) 2009-10-11
EP1523313B1 (en) 2007-11-21
NO20050676L (no) 2005-02-09
NO330254B1 (no) 2011-03-14
AU2003280958A1 (en) 2004-02-02
PL373046A1 (en) 2005-08-08
IL165747A (en) 2010-05-17
DE60317675D1 (de) 2008-01-03
AU2003280958B8 (en) 2009-02-19
UA78801C2 (en) 2007-04-25
KR20050021453A (ko) 2005-03-07
HRP20050035A2 (en) 2005-04-30
EA007463B1 (ru) 2006-10-27
JP2011144182A (ja) 2011-07-28
CN1668304A (zh) 2005-09-14
CA2393720A1 (en) 2004-01-16
HK1075839A1 (en) 2005-12-30
AU2003280958B9 (en) 2009-07-02
JP4771356B2 (ja) 2011-09-14
US8114901B2 (en) 2012-02-14
EP1523313A1 (en) 2005-04-20
DE60317675T2 (de) 2008-10-30
EA200500191A1 (ru) 2005-06-30
ES2295605T3 (es) 2008-04-16
TW200408392A (en) 2004-06-01
JP5242718B2 (ja) 2013-07-24
CN100430058C (zh) 2008-11-05
AU2003280958B2 (en) 2008-12-18
JP2006502115A (ja) 2006-01-19
US20070270465A1 (en) 2007-11-22
HRP20050035B1 (hr) 2013-07-31
ZA200500065B (en) 2006-03-29
IL165747A0 (en) 2006-01-15
WO2004006928A1 (en) 2004-01-22
KR100687165B1 (ko) 2007-02-27
US20050288332A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
MXPA02005844A (es) Inhibidores de cinasas de proteina.
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
TW200801008A (en) Protein kinase inhibitors
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
UY27712A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimientos de fabricación y utilización
BRPI0412918A (pt) inibidores de quinases p38
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA201391705A1 (ru) Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
DE60230017D1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
HRP20050035B1 (hr) Kristalniäśni 2,5-dion-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirol monohidroklorid
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE279410T1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
IS7562A (is) Sýanógúanidínforlyf